MARKET

FATE

FATE

Fate Therapeutic
NASDAQ
2.410
-0.110
-4.37%
After Hours: 2.420 +0.01 +0.42% 19:34 07/24 EDT
OPEN
2.520
PREV CLOSE
2.520
HIGH
2.545
LOW
2.400
VOLUME
1.04M
TURNOVER
--
52 WEEK HIGH
3.230
52 WEEK LOW
0.9100
MARKET CAP
280.91M
P/E (TTM)
-2.2112
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at FATE last week (0713-0717)?
Weekly Report · 5d ago
Phoenix Education Partners, Pentair And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 07/15 12:02
Weekly Report: what happened at FATE last week (0706-0710)?
Weekly Report · 07/13 10:17
Macro Note: The Tech Unwind Grew A Second Leg, And It's Healthcare
Seeking Alpha · 07/11 06:25
Fate Therapeutics (FATE) Gets a Hold from Needham
TipRanks · 07/10 10:55
Fate Gets FDA IND Clearance For FT839 To Initiate Phase 1/2 Trial In Autoimmune Diseases
NASDAQ · 07/10 07:12
Fate Therapeutics: FT839 Advancement and Autoimmune Potential Underpin Buy Rating, 12-Month $7 Price Target Reaffirmed
TipRanks · 07/09 15:25
Fate Thera gains after FDA go-ahead to advance CAR-T therapy in clinical studies
Seeking Alpha · 07/09 14:38
More
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.

Webull offers Fate Therapeutics Inc stock information, including NASDAQ: FATE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FATE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FATE stock methods without spending real money on the virtual paper trading platform.